展開再生医療の世界市場展望:幹細胞治療、組織工学、遺伝子治療...市場調査レポートについてご紹介

【英文タイトル】Translational Regenerative Medicine: Market Prospects 2016-2026

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1 Global Translational Regenerative Medicine: Market Overview
1.2 Global Translational Regenerative Medicine Market Definition and Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered By This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. An Introduction To Translational Regenerative Medicine
2.1 What Is Regenerative Medicine?
2.1.1 Translational Regenerative Medicine – From Bench to Bedside
2.2 Translational Regenerative Medicine – Market Breakdown
2.2.1 Stem Cell Therapy – Marketable Differentiation And Specialisation
2.2.1.1 How Embryonic Stem Cells (ESCs) Entered The Fray
2.2.1.2 Classifying Stem Cells by Potency
2.2.1.3 Stem Cells Categories: ESCs, SSCs, iPSCs
2.2.1.4 Parthenogenetic Stem Cells: Ethical ESC-Like Cells?
2.2.1.5 Autologous vs. Allogeneic Stem Cells: Towards Universal Stem Cell Products?
2.2.2 Tissue Engineering – In Vitro Manipulation for Therapeutic Purposes
2.2.3 Gene Therapies
2.2.3.1 Harnessing Infectivity: Viral Vectors in Gene Therapy
2.3 Other Approaches to Regenerative Medicine
2.3.1 Small Molecules and Proteins – Scaffold-Based Delivery of Signalling Molecules
2.3.2 Cosmetic Applications of Regenerative Medicine
2.4 Regulation of Regenerative Medicine
2.4.1 Regulation of Regenerative Medicine Products in Europe
2.4.2 Regulation of Regenerative Medicine Products in the US
2.5 The Phases of Clinical Trials
2.6 Market Definition
2.6.1 Products Excluded from the Report

3. Translational Regenerative Medicine Market, 2016-2026
3.1 Global Translational Regenerative Medicine: Market Overview
3.1.1 Segments within the Global Translational Regenerative Medicine Market
3.2 The Global Translational Regenerative Medicine Market in 2014 and 2015
3.3 Global Translational Regenerative Medicine: Market Forecast 2016-2026
3.3.1 Market Sectors That Will Drive Translational Regenerative Medicine Growth
3.3.2 Global Translational Regenerative Medicine Market – Changing Market Shares By Sector 2016-2026

4. Stem Cell Therapies: Leading Applications, 2016-2026
4.1 The Global Market for Stem Cell Therapies, 2014 and 2015
4.1.1 Stem Cell Therapies: Currently Available Therapies
4.1.2 Haematopoietic Stem Cell Transplantation (HSCT)
4.1.2.1 HSCT for the Treatment of Multiple Sclerosis – A Possible Cure?
4.1.3 Stem Cell Orthobiologics
4.2 Stem Cell Therapies: Global Market Forecast 2016-2026
4.3 AlloStem (AlloSource)
4.4 Osteocel Plus (NuVasive)
4.4.1 Osteocel Plus: Sales Forecast 2016-2026
4.5 Trinity ELITE and Trinity Evolution (Orthofix)
4.5.1 Trinity ELITE and Trinity Evolution: Sales Forecast, 2016-2026
4.6 PureGen (AlphaTec Spine)
4.7 Other Approved Stem Cell Therapy Products, 2015
4.7.1 Cartistem (Medipost)
4.7.2 Cupistem (Anterogen)
4.7.3 Hearticellgram-AMI (Pharmicell)
4.7.4 TEMCELL/ Prochymal/ Remestemcel-L (Mesoblast)
4.7.4.1 TEMCELL/ Prochymal (Remestemcel-L): Sales Forecast 2016-2026
4.8 Development Pipeline for Stem Cell Therapies, 2016-2026
4.8.1 Late-Stage Pipeline for Stem Cell Therapies, 2015
4.8.1.1 StemEx and NiCord (Gamida Cell)
4.8.1.1.1 StemEx Shows Improved Survival at 100 Days – but FDA Wants Another Clinical Trial
4.8.1.2 Copper Chelator Based Technology
4.8.1.3 NiCord
4.8.1.3.1 NiCord: Gamida Cell Reaches Agreement on Phase 3 Design Outline with the FDA and EMA
4.8.1.3.2 NAM Technology Platform
4.8.1.4 Mesenchymal Precursor Cell Therapies (Mesoblast)
4.8.1.5 Adult Autologous CD34+ Cells (Baxter)
4.8.1.6 MyoCell (U.S. Stem Cell Inc.)
4.8.1.7 Cx601 (TiGenix)
4.8.1.8 Adipose-Derived Stem Cells (Cytori Therapeutics)
4.8.1.9 Stempeucel (Stempeutics Research)
4.8.1.10 C-Cure (Cardio3 BioSciences)
4.8.1.11 Other Late-Stage Stem Cell Therapies
4.8.2 Diabetes and Stem Cell Therapy
4.8.2.1 Mesenchymal Precursor Cells (Mesoblast)
4.8.2.2 VC-01 (ViaCyte Inc)
4.8.2.2.1 Clinical Development Efforts for VC-01 for the Treatment of Diabetes
4.8.3 Cardiovascular Disease and Stem Cell Therapy
4.8.3.1 Endometrial Regenerative Cells (MediStem, Intrexon)
4.8.3.2 AMR-001 (Caladrius Biosciences)
4.8.3.3 CAP-1002 (Capricor)
4.8.4 Stem Cell Therapy in Cancer
4.8.4.1 CLT-008 (Cellerant Therapeutics)
4.8.4.2 OncoCyte/BioTime – Targeting Cancer with Gene and Stem Cell Therapy
4.8.5 Stem Cell Therapy for Central Nervous System (CNS) Conditions
4.8.5.1 NurOwn (BrainStorm Cell Therapeutics)
4.8.5.1.1 Clinical Development Efforts for NurOwn, 2015
4.8.5.2 NSI-566 (Neuralstem)
4.8.5.3 NSI-189 (Neuralstem)
4.8.5.4 MultiStem (Athersys)
4.8.5.5 PDA-001 (Cenplacel-L, Celgene)
4.8.5.6 ALD-401 (Cytomedix)
4.8.5.7 ReN001 (ReNeuron)
4.8.6 Stem Cell Therapy for Eye Diseases
4.8.6.1 MA09-hRPE (Ocata Therapeutics)
4.8.6.2 HuCNS-SC (StemCells Inc.)
4.8.6.3 Collaboration And License Agreement Between Pfizer And The London Project to Cure Blindness
4.9 Stem Cells Therapy Market: Drivers and Restraints 2016-2026

5. Tissue Engineering Therapies: Leading Applications, 2016-2026
5.1 The Global Market for Tissue Engineered Therapies, 2014 and 2015
5.1.1 Tissue Engineering Therapies: Currently Available Therapies
5.2 Tissue Engineering Therapies: Global Market Forecast 2016-2026
5.3 Tissue Engineering in Wound Repair and Healing
5.3.1 Apligraf (Organogenesis)
5.3.1.1 Apligraf: Historical Sales Analysis
5.3.1.2 Apligraf: Sales Forecast 2016-2026
5.3.2 BioDfence and BioDfactor (BioD)
5.3.3 CureXcell (MacroCure)
5.3.4 Dermagraft (Organogenesis)
5.3.4.1 Dermagraft (Organogenesis): Sales Forecast 2016-2026
5.3.5 Epicel (Vericel)
5.3.6 Grafix (Osiris Therapeutics)
5.3.7 MySkin and CyroSkin (Regenerys)
5.3.8 ReCell (Avita Medical)
5.3.8.1 ReCell (Avita Medical): Sales Forecast 2016-2026
5.4 Tissue Engineering for Cartilage Repair
5.4.1 Autologous Chondrocyte Implantation (ACI)
5.4.2 Carticel (Vericel Corp.)
5.4.3 ChondroCelect (TiGenix, Sobi Partners)
5.4.4 DeNovo NT (Zimmer)
5.4.5 MACI (Vericel Corp.)
5.5 Other Available Tissue Engineering Therapies
5.5.1 Autologous Cultured Cell and Tissue Products (Japan Tissue Engineering Co.)
5.5.2 Gintuit (Organogenesis)
5.5.3 LAVIV (azficel-T), (Fibrocell Science)
5.5.4 Acellular Tissue Engineering Products
5.6 Tissue Engineering: Development Pipeline, 2016-2026
5.6.1 Pipeline Products for Autologous Chondrocyte Implantation
5.6.2 Tissue Engineering for Skin
5.6.3 Tissue Engineering for Liver Diseases
5.6.3.1 Extracorporeal Bio-Artificial Liver Therapy (Vital Therapies)
5.6.4 Tissue Engineering for Cardiovascular Disease
5.6.5 Tissue Engineering for Eye Diseases
5.7 Future Prospects for Organ Transplantation and Tissue Engineering
5.8 Tissue Engineered Products Market: Drivers and Restraints 2016-2026

6. Gene Therapies: Leading Applications, 2016-2026
6.1 The Global Market for Gene Therapies, 2014 and 2015
6.2 Gene Therapies: Global Market Forecast 2016-2026
6.3 Currently Available Gene Therapy Products
6.3.1 Gendicine (Benda Pharmaceutical)
6.3.2 Oncorine (Shanghai Sunway Biotech)
6.3.3 Neovasculgen (Human Stem Cells Institute)
6.3.3.1 Neovasculgen (HSCI): Sales Forecast 2016-2026
6.3.4 Glybera (UniQure)
6.3.4.1 Glybera: Sales Forecast 2016-2026
6.4.1.4 IMLYGIC (talimogene laherparepvec) – (Amgen)
6.4.1.4.1 Clinical Trials and Development Efforts for IMLYGIC
6.4.1.4.2 Talimogene Laherparepvec (IMLYGIC) – Sales Forecast 2016-2026
6.4 Development Pipeline For Gene Therapies, 2016-2026
6.4.1 Late-Stage Pipeline Gene Therapies, 2015
6.4.1.1 Collategene (beperminogene perplasmid, AMG0001) – (AnGes MG/Vical)
6.4.1.2 ProstAtak (AdV-tk) – (Advantagene)
6.4.1.3 Trinam (taberminogene vadenovec) – (Ark Therapeutics)
6.4.1.4 AAV2-hRPE65v2 (Spark Therapeutics)
6.4.1.5 CG0070 (Cold Genesys)
6.4.2 Gene Therapy for Use in the Treatment of Diabetes
6.4.3 Gene Therapy Directed At Oncology Indications
6.4.4 Gene Therapy Directed at Neurological Diseases
6.4.5 Gene Therapy Directed at Tackling Haemophilia B
6.5 Gene Therapy Market: Drivers and Restraints 2016-2026

7. Leading National Markets for Translational Regenerative Medicine, 2016-2026
7.1 The Translational Regenerative Medicine Market by Region
7.1.1 The Global Distribution of Translational Regenerative Medicine in 2014 and 2015
7.2 Leading National Markets: Forecast 2016-2026
7.2.1 Changing Market Shares By Region, 2016-2026
7.3 Regional Translational Regenerative Medicine Markets: Analysis and Forecasts, 2016-2026
7.4 United States: The Largest Translational Regenerative Medicine Market
7.4.1 US Translational Regenerative Medicine Market: Market Drivers and Restraints, 2016-2026
7.4.2 US Translational Regenerative Medicine Market: Market Forecast 2016-2026
7.4.3 The Regulatory Framework for Regenerative Medicine in the US
7.4.4 The Impact of Ethical and Regulatory Reluctance to Embryonic Stem Cell Research and Its Impact on Funding
7.4.5 How Is the Ending of Patenting for Human Gene Products Affecting the Regenerative Medicine Market in the US?
7.5 Europe: A Fragmented Regenerative Medicine Market
7.5.1 European Regenerative Medicine Market: Market Drivers and Restraints, 2016-2026
7.5.2 European Regenerative Medicine Market: Market Forecast 2016-2026
7.5.3 Europe’s Unitary Patent System and Its Impact on the Future of Regenerative Medicine in the Region
7.5.4 Regulation of Regenerative Medicine in the European Union
7.5.5 UK: A Leading Research Centre for Regenerative Medicine in Europe
7.5.5.1 Regulation of Stem Cell Research in the UK
7.5.6 Russia: Rising Interest in Regenerative Medicine Research
7.6 Asia-Pacific: Accommodating Regulatory Landscape Aiding Rapid Product Commercialisation
7.6.1 Asia-Pacific Regenerative Medicine Market: Market Drivers and Restraints, 2016-2026
7.6.2 Asia-Pacific Regenerative Medicine Market: Market Forecast 2016-2026
7.6.3 Australia: Encouraging Translational Regenerative Medicine
7.6.4 China: Encouraging Stem Cell R&D
7.6.4.1 Government Intervention into TRM Research in China
7.6.4.2 Regulation of Stem Cell Research in China
7.6.4.3 Commercialisation of Gene Therapy and Tissue Engineering Products in China
7.6.4.4 Medical Tourism Impacting Market Growth for Regenerative Medicine in China
7.6.5 Japan: Difficulty in Translating Research into Commercialisation
7.6.5.1 Research Funding: A Major Determinant of Growth in Japan’s Regenerative Medicine
7.6.5.2 Government Interventions in Promoting Stem Cell Research in Japan
7.6.5.3 Regulation of Regenerative Medicine in Japan
7.6.5.4 Accelerating Approvals of Regenerative Medicine Products in Japan
7.6.6 India: An Emerging Market for Regenerative Medicine
7.6.6.1 Efforts in Stem Cell Research in India
7.6.6.2 Unclear Guidelines Hindering Progression of Gene Therapy Research in India
7.6.7 South Korea: First to Approve Stem Cell Treatments
7.6.7.1 A Regeneration In South Korea’s Stem Cell Research Efforts
7.7 Rest of the World: Regenerative Medicine Conquering New Territories and Booming
7.7.1 Rest of the World Regenerative Medicine Market: Market Forecast 2016-2026

8. The Leading Companies in the the Translational Regenerative Medicine Market, 2016-2026
8.1 Translational Regenerative Medicine: A Hotbed for Innovation
8.2 Alphatec Spine
8.2.1 Alphatec Spine: Financial and Performance Analysis, 2009-2014
8.2.2 Alphatec Spine’s Shifting Focus from Regenerative Medicine to Medical Devices
8.3 Anterogen
8.3.1 Anterogen: Pipeline Analysis, 2015
8.4 Athersys
8.4.1 Athersys: Financial and Performance Analysis, 2010-2014
8.4.2 Athersys: Pipeline Analysis, 2015
8.4.2.1 MultiStem Technology – Potential Treatment for a Range of Diseases
8.5 Avita Medical
8.5.1 Avita Medical: Historical Financial and Performance Analysis, 2013-2015
8.5.2 Avita Medical: Regenerative Medicine Portfolio, 2015
8.5.3 Avita Medical: Pipeline Analysis, 2015
8.6 AxoGen
8.6.1 AxoGen: Historical Financial and Performance Analysis, 2010-2014
8.6.2 AxoGen: Regenerative Medicine Portfolio, 2015
8.6.3 AxoGen: Pipeline Analysis, 2015
8.8 Medipost
8.7.1 Medipost: Historical Financial and Performance Analysis, 2010-2014
8.7.2 Medipost: Regenerative Medicine Portfolio, 2015
8.7.3 Medipost: Pipeline Analysis, 2015
8.8 Mesoblast
8.8.1 Mesoblast Product Portfolio, 2015
8.8.2 Mesoblast: Historical Financial and Performance Analysis, 2010-2015
8.8.3 Mesoblast: Pipeline Analysis, 2015
8.8.3.1 NeoFuse
8.8.3.2 Chondrogen
8.8.3.3 Prochymal / TEMCELL
8.8.3.4 Other Recent Pipeline Acquisitions by Mesoblast
8.9 NuVasive
8.9.1 NuVasive Product Portfolio, 2015
8.9.2 NuVasive: Historical Financial and Performance Analysis, 2009-2013
8.9.3 NuVasive: Pipeline Analysis, 2015
8.10 Ocata Therapeutics
8.10.1 Ocata Therapeutics: Historical Financial and Performance Analysis, 2009-2014
8.10.2 Ocata Therapeutics: Pipeline Analysis, 2015
8.10.2.1 Retinal Pigment Epithelial Cell Therapy
8.10.3 Ocata’s Other Therapeutic Platforms
8.11 Organogenesis
8.11.1 Organogenesis RM Portfolio, 2015
8.11.2 Organogenesis: Pipeline Analysis, 2015
8.12 Osiris Therapeutics
8.12.1 Osiris Therapeutics: RM Portfolio, 2015
8.12.2 Osiris Therapeutics: Historical Financial and Performance Analysis, 2010-2014
8.12.3 Osiris Therapeutics: Pipeline Analysis, 2015
8.13 Pharmicell
8.13.1 Pharmicell: Historical Financial and Performance Analysis, 2010-2014
8.13.2 Pharmicell: Pipeline Analysis, 2015
8.14 Regenerys
8.14.1 Regenerys: RM Portfolio, 2015
8.14.2 Regenerys: Pipeline Analysis, 2015
8.15 TiGenix
8.15.1 TiGenix: Historical Financial and Performance Analysis, 2011-2014
8.15.2 TiGenix: Pipeline Analysis, 2015
8.16 UniQure
8.16.1 UniQure: Pipeline Analysis, 2015
8.17 Vericel Corporation (Formerly Aastrom Biosciences, Inc.)

9. Qualitative Analysis of the Translational Regenerative Medicine Market, 2015
9.1 Market Factors Influencing the Translational Regenerative Medicine Market
9.2 SWOT Analysis of the Translational Regenerative Medicine Market, 2016-2026
9.3 Strengths
9.3.1 Improvements in Regulatory Frameworks
9.3.2 Advancements in General Cellular and Tissue Research Aiding Regenerative Medicine
9.3.3 Strong Support from Governments in Multiple Regions
9.3.4 Increasing Ease of Product Commercialisation and Market Access
9.4 Weaknesses
9.4.1 The High Price of Translational Regenerative Medicine Products May Restrain Market Growth
9.4.2 Lack of Funding from Venture Capital
9.4.3 The Intrinsic Lack of Standardisation is a Burden to Scaling up Manufacturing
9.4.4 Successful Commercialisation of TRM Products Requires New Business Models
9.5 Opportunities
9.5.1 3D Bioprinting and Other Technologies May Enable Rapid Scale-Up
9.5.2 Medical Tourism May Stimulate Standardisation and Drive Market Growth
9.5.3 Disruptive Translational Regenerative Medicine Therapies Can Create New Markets
9.6 Threats
9.6.1 Ethical Concerns Limiting R&D in Regenerative Medicine
9.6.2 Difficulty Establishing an Evidence Base For Long-Term Efficacy Of TRM Therapies
9.6.3 Rate of Scientific Progress – A Major Determinant of TRM Market Growth
9.6.4 Restraints on Reimbursement May Slow Growth
9.7 Porter’s Five Force Analysis of the Translational Regenerative Medicine Market, 2016-2026
9.7.1 Threat of New Entrants
9.7.2 Threat of Substitutes
9.7.3 Power of Suppliers
9.7.4 Power of Buyers
9.6.5 Rivalry among Competitors

10. Research Interviews
10.1 Interview with Dr Cynthia Bamdad, PhD, CEO of Minerva Biotechnologies
10.1.1 Naïve State Stem Cells Could Significantly Impact the Regenerative Medicine Market
10.1.2 On Relationships between Big Pharma and Smaller Biotech Companies in the Translational Regenerative Market
10.1.3 Growth of Minerva Biotechnologies
10.1.4 Possible New Commercial Applications for Regenerative Medicine
10.1.5 Translational Regenerative Medicine in Emerging Markets
10.1.6 iPS Cells – The Future of Stem Cell Therapies?
10.1.7 On Drivers and Restraints in the Translational Regenarative Medicine Market in 2016
10.2 Interview with Dr Yael Margolin, CEO of Gamida Cell Ltd.
10.2.1 Progress of NiCord in the Blood Cancer Indication
10.2.2 On Drivers and Restraints in the Blood Cancer Market in 2015
10.2.3 Growth of Gamida Cell Ltd.

11. Conclusion
11.1 Overview of Current Market Conditions and Market Forecast, 2014-2026
11.2 Leading Regenerative Medicine Segments in 2014 and 2015
11.3 Leading Regions in the Translational Regenerative Medicine Market in 2014 And 2015
11.4 Future Outlook for the Various Sectors within TRM, 2016-2026
11.5 R&D Pipeline Products Crucial to Future Market Growth
11.6 What Does the Future Hold for Regenerative Medicine?

12. Glossary

Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form


【レポート販売概要】

■ タイトル:展開再生医療の世界市場展望:幹細胞治療、組織工学、遺伝子治療
■ 英文:Translational Regenerative Medicine: Market Prospects 2016-2026
■ 発行日:2016年1月
■ 調査会社:visiongain
■ 商品コード:VGAIN6022519
■ 調査対象地域:グローバル
  • 世界のHetNet市場:スモールセル、キャリアWiFi、DAS、C-RAN
    Driven by in-building wireless coverage requirements and the growing influx of mobile broadband data traffic, a traditional macrocell based cellular network deployment is not deemed to be a sufficient solution to address the coverage and capacity needs of today’s wireless subscribers. Wireless carriers are thus exploring options to offload additional coverage and capacity to alternatives such as s …
  • エアコンディショニングの世界市場の世界市場2016-2020
    Covering: This market research report provides a comprehensive segmentation of the global air conditioning market by product type (air side systems, chillers, portables, single packaged, splits, and window units). It outlines the market shares for key regions such as the Americas, APAC, Europe, and MEA. The key vendors analyzed in this report are Daikin, Gree Electric Appliances, Midea, Mitsubishi …
  • スタンドアップ型ポーチの世界市場2016-2020
    About the Stand-Up Pouches Market Pouches are made of flexible or easy-yielding materials, which can easily change shape based on the nature of the product being packaged. Pouches undergo a detailed conversion process that includes printing, lamination, coating, and extrusion. A stand-up pouch contains various features to make it stand out from other type of pouches, such as zippers, spouts and fi …
  • sfRowasa(潰瘍性大腸炎):市場分析と予測(~2022)
    sfRowasa (Ulcerative Colitis) - Forecast and Market Analysis to 2022 Summary During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson’s (J&J’s) Simponi and Takeda’s Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affectin …
  • イソプロピルアルコール(IPA)の世界市場動向及び予測2015
    The present report is an essential resource for a one looking for detailed䠠information on the world isopropanol market. The report covers data on global, regional and national markets including present and future trends for supply and demand, prices, and downstream industries. In addition to the analytical part, the report provides a range of tables and figures which all together give a true insig …
  • 鎮痛薬の世界市場2016-2020
    About the Analgesics Market Analgesics are among the most commonly prescribed drugs for pain, especially that from fractures, ankle sprains, and other injuries. These are designed particularly for pain relief. Opioids, NSAIDs, and local anesthetics are the major analgesics used to treat pain. The long term use of analgesics has been linked to gastrointestinal problems. Pain is treated with analges …
  • 使い捨て麻酔機器の世界市場:呼吸回路、LMA、蘇生器、顔面マスク
    About Anesthesia Disposables Healthcare-acquired infections (HAI) are a major threat to patients’ safety. Organizations like the CDC and Public Health England monitor healthcare settings through routine surveillance programs to identify the infection type and make efforts toward prevention. According to the CDC, in 2015, one in 25 patients in the US suffered from HAI during hospital care. To preve …
  • 医療レポート:Uveitis-疫学予測(~2022)
    EpiCast Report: Uveitis - Epidemiology Forecast to 2022 Summary Uveitis is a serious eye condition that often results in permanent vision damage due to frequent recurrence even after treatment. It consists of a group of diseases that present with inflammation of the uvea, can occur in one or both eyes, and may also affect the adjacent tissues such as the retina, optic nerve, and vitreous humor. Sy …
  • 世界の水産飼料市場
    Fish require energy and essential nutrients for body-maintenance, movement, normal metabolic functions, and growth. Fish can obtain their energy and nutrients from natural food in ponds, from feed supplied by the farmers or from a combination of both the sources. Feed is a major expenditure for fish farmers as it accounts for 40% - 50% of the production cost. The global aquafeeds market is estimat …
  • Respiratory Diseases in the US 2014: Market Outlook and Emerging Opportunities
    About This ReportThis new 283-page report from Venture Planning Group presents detailed analysis of the US Respiratory Diseases market, including sales forecasts and supplier shares for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis.  The report provides test volume and sales projections for Hospitals, Physician Offices, Commercial, and Public He …
  • American Natural Energy Corporation:石油・ガスの開発・生産動向及びコスト分析- 2012
    American Natural Energy Corporation Oil & Gas Exploration and Production Operations and Cost Analysis - 2012 Summary American Natural Energy Corporation Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The repor …
  • ホルモン不応性前立腺癌:世界の臨床試験レビュー(2014年上半期)
    Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate clinical trial scena …
  • 2014年戦略提言:ヨーロッパの呼吸器病診断検査市場
    Complete report $8,300.  DataPack (test volumes, sales forecasts, supplier shares) $5,400.This new 335-page report from Venture Planning Group provides analysis of the European respiratory disease testing market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares, and strategic profiles of leading suppliers.  About this ReportThis report pr …
  • 地域別WiMAXサービスプロバイダー(WiMAX Service Providers by Country 2012)
    WiMAX service providers have a rich environment to create real business, not only providing services to traditional customers, but also to developing a solid ecosystem with other technology developers which are seeking for enhancing their WiMAX-based developed products. This developed ecosystem facilitates certain advantages for all ecosystem partners and such advantages are reflected to customers …
  • 低温液化ガス用機器の世界市場:タンク、バルブ、気化器、ポンプ、トンネル式フリーザ、デュワー、ストレーナー
    The report estimates the global cryogenic equipment market share in terms of products sold, which has been further subdivided into different types, their applications based on various industries, and regions, which have been split further country-wise. Cryogenic equipment is used to store, transfer, handle, and supply liquefied gases such as nitrogen, oxygen, and argon among other gases. The most …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。